Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sanigen Co (188260) Fair Value & Analysis

Healthcare · KR · Market cap 12.0B KRW

Price1,596 KRW
Fair Value1,047 KRW
Upside-34.4%
Quality95/100
Evidence: Low Range 785.06 KRW – 1,308 KRW

Fair value as of: Jun 24, 2026

Analysis

Sanigen Co (188260) currently trades at 1,596 KRW, while our model-based Fair Value estimate is 1,047 KRW — implying the stock looks roughly 34.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Sanigen Co. Ltd, a food sanitation and safety specialist, develops and services solutions for safe food manufacturing, distribution, and sales in Korea and internationally. The company offers PCR detection and nucleic acid extraction kits; bag, diluent, beam template, macroswab, and squeeze products; pathogen detection NGS panel kits; and hand sanitizers, vomit clean up kits, and pure systems. It also provides Microbial, physicochemical analysis, and food sanitation/lab services. Sanigen Co. Ltd was founded in 2005 and is headquartered in Anyang-si, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Sanigen Co (188260) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 1,047 KRW versus a price of 1,596 KRW — about −34% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 188260?
Our 21-model fair value for Sanigen Co is 1,047 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 1,596 KRW.
What is the quality score of 188260?
Sanigen Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.